Corporate VCs Do More than Their Fair Share of Private Biotech Financing
This article was originally published in Start Up
Executive Summary
Although venture capitalists have cut back the amount of money they invested in private biotechs during the 2001-2003 timeframe, corporate VCs bucked the trend and continued to participate consistently in supporting these firms with equity investments.
You may also be interested in...
Abbott Ventures: Building A Venture Portfolio in Devices
Corporate venture investing has become an increasingly important source of capital as traditional venture firms remained squeezed. In devices, the latest entrant into the field is Abbott Ventures, which sees itself as an extension of Abbott's internal efforts to build its device pipeline, favoring mid-stage deals in technology and therapeutic areas that fit strategically with Abbott's existing device businesses.
Abbott Ventures: Extending Horizons in Abbott's Device Pipeline
Corporate venture investing has become an increasingly important source of capital as traditional venture firms remained squeezed. In devices, the latest entrant into the field is Abbott Ventures, which sees itself as an extension of Abbott's internal efforts to build its device pipeline, favoring mid-stage deals in technology and therapeutic areas that fit strategically with Abbott's existing device businesses.
Novartis' Competing Venture Funds Pursue Lower-Cost Innovation
As biotech deal prices skyrocket, pharma's trying to get in on the ground floor, hoping for a bargain. But innovation-for-less is tough to engineer, and not everyone agrees on how it can be nurtured--and who is best placed to do the nurturing. Novartis now has two competing groups pursuing lower-cost venture-based paths to innovation. Neither, apparently, wants much to do with the other.